InsidersTradesSigma
Track the Johnson & Johnson share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Johnson & Johnson has recorded 241 reports. Market capitalisation: €645.9bn. The latest transaction was disclosed on 4 September 2026 (Levée d'options). Among the most active insiders: Duato Joaquin. Every trade is free.
241
Insider Decl.
n/a
Thresholds
€362,938
2 ops.
Buy Volume
€79m
33 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Johnson & Johnson Buy (bullish), based on 22 analysts. Average price target: US$272.50.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 6,455 of 29,063 companies
65.5
score / 100
Value49
Quality82
FCF yld3.0%
Earn yld4.1%
EV/EBITDA16.9x
ROE26%
Gross mgn68%
Net mgn28%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations241 total
11,070 shares@ US$131.94Common StockSEC:0000200406-26-000179:0
11,070 shares@ US$274.74Common StockSEC:0000200406-26-000179:1
22,527 shares@ US$151.41Common StockSEC:0000200406-26-000179:2
22,527 shares@ US$274.74Common StockSEC:0000200406-26-000179:3
15,000 shares@ US$115.670.0003% mcap6.2% of flowCommon StockSEC:0000200406-26-000175:0
15,000 shares@ US$263.360.0006% mcap14.0% of flowCommon StockSEC:0000200406-26-000175:1
15,000 shares@ US$263.36120.0006% mcap17.6% of flowCommonSEC144:0001959173-26-006082
123,291 shares@ US$115.670.0023% mcap9.0% of flowCommon StockSEC:0000200406-26-000173:0
20,976 shares@ US$262.000.0009% mcap3.5% of flowCommon StockSEC:0000200406-26-000173:1
102,315 shares@ US$261.000.0042% mcap16.8% of flowCommon StockSEC:0000200406-26-000173:2
123,291 shares@ US$261.17010.0051% mcap28.7% of flowCommonSEC144:0001959173-26-005985
41,957 shares@ US$258.0560.0017% mcap13.5% of flowCommon StockSEC:0000200406-26-000171:0
6,523 shares@ US$258.7390.0003% mcap2.1% of flowCommon StockSEC:0000200406-26-000171:1
9,344 shares@ US$131.940.0002% mcap10.4% of flowCommon StockSEC:0000200406-26-000169:0
9,344 shares@ US$257.7550.0004% mcap20.3% of flowCommon StockSEC:0000200406-26-000169:1
6,574 shares@ US$255.9320.0003% mcap14.2% of flowCommon StockSEC:0000200406-26-000169:2
15,918 shares@ US$257.0020.0007% mcap62.5% of flowCommonSEC144:0001959173-26-005706
48,480 shares@ US$254.930.0020% mcap100.0% of flowCommon StockSEC144:0001968582-26-000782
11,129 shares@ US$129.510.0002% mcap8.5% of flowCommon StockSEC:0000200406-26-000148:0
11,925 shares@ US$131.940.0003% mcap9.3% of flowCommon StockSEC:0000200406-26-000148:1
23,054 shares@ US$251.2660.0010% mcap34.3% of flowCommon StockSEC:0000200406-26-000148:2
23,054 shares@ US$251.26610.0010% mcap71.7% of flowCommonSEC144:0001959173-26-005284
10,000 shares@ US$240.15390.0004% mcap12.0% of flowCommonSEC144:0001959173-26-004553
4,075 shares@ US$115.679.3% of flowCommon StockSEC:0000200406-26-000048:0
1,322 shares@ US$245.6617.0% of flowCommon StockSEC:0000200406-26-000046:0
25 of 241 declarations
关于 Johnson & Johnson
强生公司（Johnson & Johnson）是一家领先的美国医疗保健公司，在纽约证券交易所上市，股票代码为JNJ，总部位于美国新泽西州新不伦瑞克。公司成立于1887年，已在全球医疗保健领域建立了最持久的特许经营权之一，业务遍及几乎所有国家，其商业模式以规模、创新和多元化为基础。对于法国、比利时和瑞士的投资者而言，JNJ通常被视为一家高质量的防御性大盘股，将制药创新与医疗技术敞口相结合，并拥有悠久的价值创造和股息增长记录。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0000200406/000130817925000085/jnj013333-ars.pdf)） 强生公司目前分为两个核心运营部门：创新药物和医疗技术。创新药物涵盖免疫学、传染病、神经科学、肿瘤学、肺动脉高压以及心血管和代谢疾病等主要治疗领域的研究、开发、制造和商业化。医疗技术汇集了骨科、外科、心血管护理和视力方面的广泛解决方案组合。这种更简单的结构使投资者能够更清晰地了解集团的战略重点，并强调其对高价值医疗保健类别的关注。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0000200406/000130817925000085/jnj013333-ars.pdf)） 从竞争角度来看，JNJ受益于多项结构性优势：强大的全球品牌、深厚的研发能力、广泛的临床和商业足迹以及涵盖药物和医疗设备的多元化产品组合。公司在高度监管、创新驱动的市场中竞争，知识产权、临床执行和监管批准至关重要。其产品和服务销往美国和国际市场的医院、医生、分销商、零售商和医疗保健专业人员。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0000200406/000130817925000085/jnj013333-ars.pdf)） 主要特许经营权包括免疫学和肿瘤学疗法，以及先进的医疗设备和外科技术。公司继续强调肿瘤学、自身免疫疾病和外科创新领域的下一代平台，支持中期增长潜力，同时平衡一些传统类别的成熟度。（[jnj.com](https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results)） 近期亮点包括发布2025年全年业绩、2025年季度股息增加、多项监管批准和产品发布，以及2025年10月宣布计划分拆骨科业务以加强战略和运营重点。总体而言，强生公司仍然是大型医疗保健领域的一个转型故事，在现金生成、创新和投资组合重塑之间保持着弹性平衡。（[jnj.com](https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results)）
